Subscriber vs. Insured

In insurance, a subscriber is the person who pays the insurance premium and is typically the policyholder or the primary contact for an insurance plan. On the other hand, the insured is the person or entity that is covered by the insurance policy. It is possible for the subscriber and the insured to be the same person, but this is not always the case.

Here is an example to illustrate the difference between a subscriber and an insured:

John works for ABC Corporation, which offers health insurance coverage to its employees. ABC Corporation pays the premium for the insurance plan, making it the subscriber. However, John and his family are the individuals covered by the insurance policy, making them the insured. In this case, John is not the subscriber but rather the insured.

Key features of a subscriber vs. insured include:

Subscriber:

  • Pays the insurance premium
  • Typically the policyholder or primary contact for the insurance plan
  • Can be an employer or an individual

Insured:

  • Person or entity that is covered by the insurance policy
  • Can be a dependent or an employee of the subscriber
  • May or may not be the same as the subscriber

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.